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A relative immunosuppression is observed in patients
after sepsis, trauma, burns, or any severe insults. It is
currently proposed that selected patients will benefit
from treatment aimed at boosting their immune
systems. However, the host immune response needs to
be considered in context with pathogen-type, timing,
and mainly tissue specificity. Indeed, the immune status
of leukocytes is not universally decreased and their
activated status in tissues contributes to organ failure.
Accordingly, any new immune-stimulatory therapeutic
intervention should take into consideration potentially
deleterious effects in some situations.Arbitrarily classifying cytokines as pro- or
Introduction
Refinements of supportive care of patients with severe sep-
sis have decreased their overall mortality, but no adjuvant
drug therapy has emerged despite strenuous efforts in the
field. Twenty years have passed since the first patients with
sepsis were included in clinical trials based on the under-
standing that TNF orchestrates the inflammatory response
and should be the target for therapeutic intervention. In re-
sponse to the failure of therapies aiming to target either
the up-stream microbial activators or the effector mole-
cules of the inflammatory cascade, a new concept has
emerged of boosting the immune system to counter im-
munosuppression that develops in patients who survive
the initial, hyperinflammatory period of sepsis [1].
Inflammation is a highly sophisticated and complex re-
sponse that fundamentally ‘aims’ to protect the host. In
this review, we argue against the promulgation of what
we believe is a misleading perception of sepsis inducing
secondary immunosuppression. The possible negative
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2014so great that we believe such an approach should be
considered with great caution.
It is important to realize that events occurring in patients
with sepsis are not a simple dichotomy resulting from a
balance between pro-inflammatory and anti-inflammatory
mediators. Oversimplification may have led to previous
therapeutic failures. Maintaining such an over-simplistic
analysis of inflammation may lead to further failed trials,
compounding our current state of therapeutic futility in
sepsis. By reviewing the immunological events of sepsis, we
also attempt to understand why we have already spent over
20 fruitless years trying to reverse it with targeted adjuvant
therapies.anti-inflammatory mediators is unreliable
Classifying cytokines as pro- or anti-inflammatory has led
to oversimplification of the inflammatory response. Con-
sequentially, especially in a disorder as complex as sepsis,
simplistic therapeutic approaches have been considered.
The inappropriateness of this classification is widely
illustrated by studies revealing some paradoxical behaviors
of so-called pro- and anti-inflammatory cytokines. In re-
gard to TNF, the prototypic ‘pro-inflammatory’ cytokine,
TNF-treated murine macrophages produced less IL-12
and IL-23 after IFNγ and lipopolysaccharide (LPS) stimu-
lation [2]. In vivo, TNF induces extra-adrenal production
of immunoregulatory glucocorticoids in the intestinal mu-
cosa during acute intestinal inflammation [3]. Similar ob-
servations have been reported for other pro-inflammatory
cytokines such as IL-1 and IFNγ. In a dextran sulphate
sodium-induced colitis model, mice deficient in IL-1RI
signaling showed increased susceptibility to and failed to
mount a protective type I interferon response after Toll-
like receptor (TLR) 9 ligand administration [4]. Further-
more, IFNγ knockout (KO) mice had significantly greater
endotoxin-induced uveitis as compared with wild-type
mice, and the injection of murine IFNγ suppressed the se-
verity of endotoxin-induced uveitis in both wild-type and
KO mice [5].al Ltd. The licensee has exclusive rights to distribute this article, in any medium,
this time, the article is available under the terms of the Creative Commons
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10, the prototypic anti-inflammatory cytokine. Its pro-
inflammatory activity been established in human volun-
teers receiving endotoxin injection [6]. Our own in vitro
studies showed that adherence of human monocytes
modulated the effect of IL-10 on expression of 16 genes,
including ‘suppressor of cytokine stimulation’ (SOCS)
molecules, in the opposite direction as compared with
non-adherent cells [7]. These observations illustrate the
statement by Moore and colleagues that ‘IL-10 can effect
very different outcomes depending on timing, dose, and
location of expression. In some scenarios, the expected
immuno-suppressive activities are observed, while in
others, IL-10 enhances immune or inflammatory re-
sponses’ [8].
Among other cytokines classified as anti-
inflammatory, transforming growth factor-beta (TGFβ)
may behave as pro-inflammatory mediator as TGFβ-
transgenic mice are more sensitive to LPS-induced
shock [9] and some of its inflammatory activities reflect
its capacity to favor the differentiation of T helper (Th)
17 and production of the pro-inflammatory IL-17. The
classification of non-cytokine inflammatory mediators
also relies on an overly simplistic division between pro-
and anti-inflammatory properties. This is well illustrated
by prostaglandin E2 (PGE2), a key mediator of infectious
immunopathology. On one hand, PGE2 induces fever, in-
creases vascular permeability, increases vasodilatation,
and causes pain while also inhibiting production of TNF,
increasing production of IL-6, inhibiting 5-lipoxygenase
and leukotriene A4 generation, and inducing 15-
lipoxygenase and the generation of the lipoxins involved
in inflammation resolution. On the other hand, PGE2
has inhibitory properties on macrophages, neutrophils,
Th1 lymphocytes, natural killer (NK) cells, and cytotoxic
lymphocytes but activates mast cells, Th2, Th17, and
regulatory T lymphocytes (Treg) [10]. This panoply of
PGE2-stimulated events amply demonstrates the inability
to simply characterize the activities of this and the other
molecules mentioned as pro- or anti-inflammatory.
Sometimes-ambiguous roles of cytokines in
infection and sepsis
In an early anti-TNF monoclonal antibody intervention
study, a significant improvement in day 3 survival was
observed between the antibody-treated group and the
placebo group [11]. Although this was not a pre-
specified primary outcome, it is interesting to see that
the treatment targeting TNF consisting of a single early
injection was beneficial within a short period of time
after sepsis onset, reinforcing the idea that TNF plays a
key deleterious role in the early events of sepsis. Once
anti-TNF treatments were better targeted to the sickest
patients by adding biological inclusion parameters(plasma IL-6 level), survival was significantly improved
on day 28 [12].
Synergistic effects between immune modulators are a
key characteristic of their effect. This explains how a
non-lethal dose of one cytokine can lead to mortality
when injected with a non-lethal dose of another cyto-
kine. Similarly, it may explain how the removal of some
inflammatory mediators by coupled plasma filtration-
adsorption was protective in an endotoxin-shock model
while levels of circulating bio-active TNF were un-
affected [13].
Clear demonstrations of cytokine-mediated tissue
damage exist. Nevertheless, because of their ambiguous
role mentioned above, identification of their precise role
during sepsis has led to controversy. In animal models
of sepsis, the role of TNF may vary depending upon the
type of infection [14]. Many model parameters influence
conclusions of the relative role of the different mediators
studied. Identical cytokines have been found to be pro-
tective or deleterious depending upon the model. This
has been the case for IFNγ [15] and granulocyte-
macrophage colony-stimulating factor (GM-CSF) [16]
among others (for example, IL-17, IL-33, ‘TNF-related
apoptosis-inducing ligand’ (TRAIL), and TGFβ).
Opposing effects of immune cells in sepsis
Host-protective innate immune responses and conse-
quent inflammation are inextricably linked and overlap-
ping. Consequently, the same cellular actors are key
elements defending the host against infection while sim-
ultaneously contributing to deleterious events. For ex-
ample, neutrophil extracellular traps that catch and kill
bacteria and fungi are associated with the release of ele-
ments such as histones and mitochondria that behave
like damage-associated molecular patterns perpetuating
the inflammatory process.
Beneficial or deleterious roles of the same leukocyte
subset have been reported depending upon the experi-
mental model. For example, a peritonitis model using
nude mice (lacking T cells) suggested that T lympho-
cytes contribute to protective immune responses [17].
By contrast, in an Escherichia coli sepsis murine model,
T lymphocytes markedly contributed to severity [18].
Similarly, Treg improved survival in polymicrobial sepsis
[19] whereas, in another report, reduced Treg activity led
to improved survival [20]. The ‘half angel/half devil’ role
of NK cells during severe infection is also described. NK
cells contribute to systemic inflammation during polymi-
crobial sepsis but play a critical protective role in host
defense against Staphylococcus aureus lung infection (as
reviewed in [21]). Although apoptosis of dendritic cells
(DCs) is particularly increased during sepsis, they are
protective in murine polymicrobial sepsis [22]. Tran-
scriptomic analysis of DCs in trauma patients shows a
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gesting their contribution to systemic inflammation and
organ failure [23].
Apoptosis of lymphocytes, DCs, and NK cells is a hall-
mark of sepsis. Hotchkiss and colleagues [24] provided
key experiments demonstrating that lymphocyte apoptosis
was deleterious and its prevention highly protective. In
addition to the depletion of apoptotic lymphocytes that
contribute to the alteration of the immune status, apop-
totic T cells themselves can further produce an immuno-
suppressive milieu following their release of TGFβ [25]. In
contrast, the apoptosis of neutrophils is reduced. Interest-
ingly, injection of apoptotic neutrophils in LPS-challenged
mice with or undergoing cecal ligature puncture improved
outcomes [26]. This may be due to the capacity of apop-
totic neutrophils to limit the production of IL-1 and TNF
by LPS-activated monocytes and to favor the production
of IL-10 and TGFβ [27]. Favoring neutrophil apoptosis
while differentially preventing that of lymphocytes and
DCs would represent a considerable interventional
challenge!
Inflammatory mediators and their effects in
various organ compartments promote organ
failure
In sepsis, apoptosis does not only affect immune cells.
Apoptosis of epithelial cells, endothelial cells, neurons, and
cardiac myocytes is reported with crucial effects of loss of
altered barrier function (Figure 1): in the lungs - acute lung
injury and adult respiratory response syndrome [28]; in the
kidneys - acute kidney injury [29]. Enhanced translocation
of bacteria and bacterial products occurs consequent onFigure 1 During sepsis, many types of cells (but not neutrophils) disp
consequences. AKI, acute kidney injury; ALI/ARDS, acute lung injury/acuteintestinal epithelial cell apoptosis [30], contributing to the
concept of the gut as the motor of multiple organ failure
(MOF). Sepsis-induced cardiac myocyte apoptosis pro-
duces altered contractility and cardiac dysfunction [31].
Apoptosis of endothelial cells [32] induces vascular leakage.
Finally, microglial and neuronal apoptosis may follow auto-
nomic failure that precedes shock and MOF [33].
In addition to epithelial apoptosis, tight junction alter-
ations enhance organ dysfunction. It has been demon-
strated that nitric oxide favors disruption of epithelial cell
tight junctions in numerous organs, including liver, gut,
and lung. Leukotrienes favor protein extravasation as
shown in the kidney of septic mice [34].
Still, cytokines remain the main orchestrators of these
tissue injuries. In a model of acute kidney injury, it was
nicely demonstrated that inflammatory cytokines, in-
cluding TNF and IL-17, cause small intestine and liver
injury [35]. Among others, IL-17A is critical for gener-
ation of intestinal ischemia/reperfusion injury and subse-
quent liver and kidney injury [36]. All together, the
altered functions of epithelial cells, endothelial cells,
neurons, and cardiac myocytes contribute to MOF that
may influence outcomes in sepsis more than altered im-
mune status.
The concomitant occurrence of inflammation,
anti-infectious response, and altered immune
status in sepsis
When Roger Bone coined the concepts of systemic in-
flammatory response syndrome (SIRS) and compensa-
tory anti-inflammatory response syndrome (CARS), he
conceived that one or the other would be predominatinglay enhanced apoptosis, leading to various deleterious
respiratory distress syndrome; NK, natural killer.
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ered an adapted compartmentalized response with the
aim of silencing some acute pro-inflammatory genes and
maintaining the expression of certain genes involved in
the anti-infectious process. Despite our views [38], authors
still propose a two-wave concept with SIRS appearing be-
fore CARS, although they admit that ‘rigorous examin-
ation of previous studies provides evidence that both pro-
inflammatory and opposing anti-inflammatory response(s)
occur concomitantly in sepsis’ [1].
Tamayo and colleagues [39] studied a large panel of cir-
culating cytokines in patients with SIRS or sepsis, con-
cluding that both pro- and anti-inflammatory mediators
play roles from the very beginning of this life-threatening
condition. Similarly, meta-analysis of 12 transcriptomic
studies including 784 individuals led to the conclusion
that ‘the arbitrary distinction of separating sepsis into pro-
inflammatory and anti-inflammatory phases is not sup-
ported by gene-expression data’ [40].
Immune status has been studied frequently by measur-
ing TNF or other inflammatory cytokine production by
circulating monocytes in response to LPS [41]. We studied
patients undergoing abdominal aortic surgery, showing
that reduced expression of human leukocyte antigen
(HLA)-DR on CD14HIGH monocytes occurs during sur-
gery [42]. Similarly, HLA-DR expression was already re-
duced on monocytes taken very soon after severe trauma
at accident scenes [43]. Altered TNF production capacity
of circulating cells in response to TLR2 or TLR4 agonists
is also observed very soon after injurious insults, such as
on admission of patients after cardiac arrest [44]. Even if
soon after the initial insult the intensity of the inflamma-
tory response reaches its peak, there is a persistent inflam-
mation associated with altered immune status in surviving
patients [45]. The more severe the insult, the more pro-
found is the alteration and the more chance the patients
have to develop adverse clinical outcome.
The immune status of leukocytes during sepsis
and SIRS varies depending on the compartment
in which they reside
Terms such as ‘immunoparalysis, immunosuppression,
and anergy’ are far too extreme to describe the immune
status of circulating leukocytes in patients with sepsis or
SIRS. Altered immune status of circulating leukocytes is
not globally present. Indeed, some functions like phago-
cytosis remain unaltered [46], and ex vivo cytokine pro-
duction in response to heat-killed S. aureus (HKSA)
remains unchanged in patients with sepsis [47] com-
pared with healthy controls. This is in full agreement
with the observation that LPS primes HKSA-induced
TNF production in macrophage cell lines instead of
leading to cross-tolerance [48]. While the concept of
endotoxin tolerance is considered to partially mimic thealteration of immune status in sepsis, it is worth men-
tioning that cross-tolerance between microbial agonists
is not invariant. For example, Candida albicans and fun-
gal cell wall β-glucan also prime LPS-induced pro-
inflammatory cytokine production [49].
These observations led us to propose the concept of
leukocyte reprogramming [50] to explain the fact that
tolerised macrophages retain anti-infectious properties. In
addition, in tissues, there are numerous examples to illus-
trate the hyper-activity of these cells. For example, in mice
with polymicrobial sepsis alone or as a ‘second hit’ after
traumatic hemorrhage, it was nicely demonstrated by
Chaudry’s group [51] that the ex vivo production of TNF
or IL-6 after LPS activation was significantly reduced
among peripheral blood mononuclear cells and splenic
macrophages but that it was enhanced in alveolar and
Kupffer cells. Similarly, in a murine model of trauma, the
cytokine productive capacity of Kupffer cells and alveolar
macrophages was enhanced [52]. Indeed, macrophage
functions differ depending on the compartment from
which they derive. We established [53] that the specific
cytokine and cellular microenvironment within the lung
was responsible for this particular resistance of alveolar
macrophages to endotoxin tolerance, which can also be
observed in human alveolar macrophages [54]. Similarly,
in kidneys, in response to a second challenge with LPS,
the expression of TNF and inducible nitric oxide synthase
was further enhanced [55]. This may explain why unilat-
eral nephrectomy could be protective in a murine periton-
itis model and after LPS injection [56]. Most importantly,
despite the fashionable concept of M1/M2 macrophages,
the response of macrophages to IL-4 and IFNγ is in fact
completely different depending upon their origin [57]. As
a consequence of this great heterogeneity of immune cells
within different compartments, each tissue behaves inde-
pendently, contributing to the global inflammatory re-
sponse with a specific pattern, as illustrated by differential
cytokine expression in liver, lungs, heart, brain, muscle,
kidney, intestine, and spleen [58]. Another example of the
different behavior of leukocytes in various compartments
is the frequent occurrence of hemophagocytosis (>60%)
directly observed in the bone marrow of the critically ill
[59]. This phenomenon is associated with extreme pro-
duction of inflammatory cytokines. Accordingly, it has
been proposed that when hemophagocytosis is diagnosed
in critical care patients, aggressive immunosuppressive
therapy be undertaken without delay [59].
Differences between cells harvested from different
compartments after sepsis have also been reported for
spleen and peritoneal myeloid DCs [60]. The major dif-
ferences between compartments are further illustrated
by the fact that gene deficiency may differentially affect
outcomes of infection. For example, IL-10 deficiency
protects against Francisella tularensis pulmonary
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larly, we showed that scavenger receptor-A (SR-A),
‘macrophage associated receptor with a collagenous
base’ (MARCO), CD36, or TLR2 deficiency protect mice
against peritoneal S. aureus infection while these defi-
ciencies aggravated pneumonia [62]. Interestingly, when
Streptococcus pneumoniae was the pathogen used to
colonize the murine nasopharynx, MARCO KO mice
(but not SR-A KO mice) had significantly impaired
clearance of pneumococcal colonization [63].
Furthermore, inflammatory foci cells may not behave
similarly to cells from other healthy compartments. For
example, it was shown that neutrophils derived from
sputum of patients with chronic bronchitis or cystic fi-
brosis are insensitive to inhibitory effects of IL-10 in
contrast to circulating neutrophils [64].
Murine models poorly mimic the clinical settings
The concomitant presence of inflammation within tissues
and altered immune status within the hematopoietic com-
partment is short-lived in murine models rendering them
inappropriate to study patients with concomitant sepsis
and CARS [65]. In addition, mice are highly resistant to
bacteria like S. aureus and their serum contains factors
that limit inflammatory response intensity as compared
with human serum [66]. A most provocative report com-
paring transcriptomic patterns of circulating cells from
trauma patients, human endotoxemia-model participants,
and murine-model equivalents revealed total absence of
correlation [67]. When most therapeutic approaches have
been validated in preclinical studies performed with mur-
ine models, one understands why those were not the most
appropriate ones.
The scientific community needs to reconsider models
used to validate therapeutic approaches. If murine re-
sponses do not resemble human processes, maybe other
species, like the pig, should be preferred. Porcine mono-
cytes and LPS-activated macrophages are closer to their
human counterparts than murine cells [68]. Of course,
murine models remain valuable to further decipher the
mechanisms of sepsis. The best example is the two-hit
model, which demonstrated that the nature of the first
hit and its severity, the nature of the infection, and the
route of infection may influence the outcome in a com-
pletely opposite direction [69].
Are patients with sepsis dying of immune
failure - dissecting the arguments used to
describe compensatory immunosuppression
occurring after sepsis?
The clinical observations used to argue that immuno-
suppression occurs in sepsis patients surviving the initial
inflammatory cascade [1] are in essence that patients
develop nosocomial infections due to opportunisticpathogens, including reactivated chronic viral infections,
and that patients who die after sepsis have unresolved
foci of infection. These underpinning observations re-
quire further consideration.
Representing bacteria such as Enterococcus faecium,
Stentrophomonas maltophilia, and Pseudomonas aerugi-
nosa along with Candida as ‘opportunistic pathogens’
overstates the role of sepsis-induced immune dysregula-
tion as the primary cause of nosocomial infection in these
patients. These multiply-instrumented, high-intensity care,
bed-bound, vulnerable patients often have breaches in
their integument and mucous membranes (airways, surgi-
cal sites, indwelling catheters) and perturbed microbiomes
from antibiotic treatments. Overgrowth of antibiotic-
resistant microorganisms and barrier defects predispose
them to secondary infections, even without overt defects
in their immune defenses [70]. These are all organisms of
normal virulence that cause nosocomial infections in sep-
sis patients because of the selection pressure of potent an-
tibiotics and the presence of biofilm affected/colonized
intravascular and urinary catheters.
Additionally, reactivation of herpes simplex virus (HSV)
and cytomegalovirus (CMV) may have some clinical rele-
vance in critically ill patients. CMV-emia is quite common
in patients with sepsis (30% in some studies) and is at least
associated with worse outcome in ICU patients in recent
meta-analyses. Whether CMV could cause immune com-
promise itself, be a reflection of immune compromise, or
simply be an indicator of poor outcome in patients with
sepsis remains unclear [71]. Reactivation of oro-labial
HSV is extremely common in sepsis, and HSV can fre-
quently be detected in respiratory secretions. However,
only one study has reliably investigated lower respiratory
tract infection in critically ill, immunocompetent patients,
showing that 21% of patients with ventilator-associated
pneumonia (VAP) had bronchopneumonitis due to HSV
[72]. In 55% of these patients, the VAP appeared to be due
to HSV alone. However, acyclovir treatment had no im-
pact on the outcome in patients with HSV bronchopneu-
monitis [72]. Of greater relevance to predisposition to
nosocomial infection in sepsis patients remaining in ICUs
for prolonged periods are physical breaches in innate im-
mune system barriers. Intravascular catheters, endo-
tracheal tubes with consequently increased dead space,
and increased gastric pH due to peptic ulcer prophylaxis
regimens are all, along with broad-spectrum antibiotics,
potent promoters of nosocomial infection.
Post-mortems (PMs) identifying unresolved infection
foci are not reliable proof that patients are dying of sep-
sis. Pneumonia is frequently present in patients in whom
supportive care is withdrawn due to failure to thrive.
Where pneumonia has been found more frequently at
PM than was appreciated ante-mortem, the extent of
pulmonary involvement was not quantified [73]. In this
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sessment that MOF was the commonest cause of death
[73]. These data call into question the relevance of unre-
solved, PM infection in patients dying in the ICU as a
direct indicator of immunosuppression following as a
direct consequence of previous sepsis. If the patients die
with infectious foci and altered immune status, it does
not mean they die because of them.
Boosting the immune system
Because of the monocyte deactivation in sepsis, it was
proposed to restore it with the use of either IFNγ or
GM-CSF, two cytokines that counteract endotoxin toler-
ance. The first attempt was successfully performed in
nine septic patients who received subcutaneous IFNγ
that restored ex vivo cytokine production and HLA-DR
expression by monocytes [74]. The authors claimed that
overall mortality was lower in the treated group com-
pared with historical controls. In mechanically ventilated
trauma patients, IFNγ was aerosolized. However, in a
previous phase III study in burn patients, IFNγ had
failed to protect patients from infection or decrease
mortality [75]. We must recall that IFNγ injection in-
creases mortality in animal models of polymicrobial in-
fection [15]. All together, these data have limited the
routine use of IFNγ in ICU patients, although a Dutch
clinical trial is ongoing.
GM-CSF has been demonstrated to be able to restore
some immune status parameters. However, a meta-
analysis concluded that GM-CSF did not significantly
reduce in-hospital mortality, although it significantly in-
creased infection recovery [76]. Although no adverse ef-
fects were reported, it is worth recalling a case report of
a patient who developed a fatal adult respiratory distress
syndrome after GM-CSF treatment [77]. In animal
models, GM-CSF favors LPS-induced lung inflamma-
tion, amplifying LPS-induced bronchoconstriction [78].
GM-CSF favors production of TNF and IL-1. In a recent
study, it was confirmed that GM-CSF synergizes with
LPS, promoting IL-1β secretion [79]. Lethal injection of
LPS in GM-CSF receptor KO mice led to far lower mor-
tality among these mice as compared to wild type mice.
Given all the efforts made by some authors to convince
the scientific community of the use of GM-CSF, it is
challenging to read the conclusion of this present paper
given that GM-CSF has been previously underestimated
as a target for therapeutic intervention in many bacterial
infections and inflammatory disorders associated with
the production of IL-1β.
IL-7 is another cytokine that is promoted for the treat-
ment of sepsis and that is supported by murine and hu-
man ex vivo tissue data [1,80]. One can conjecture that
systemic treatment with IL-7 may act in undesired
places, as illustrated by the following: IL-7 worsensgraft-versus-host-induced tissue inflammation [81]; favors
inflammation in colitis [82], contributes to arthritis sever-
ity [83]; upregulates chemokines, IFNγ, macrophage
recruitment, and lung inflammation [84]; and, finally, in-
creases production of inflammatory cytokines by mono-
cytes and T cells [85].
Many other cytokines (for example, IL-2, IL-12, IL-15,
and TNF) can boost the immune system and are reported
to be beneficial in murine sepsis models. However, one
wonders whether systemic treatment with any immunosti-
mulating cytokine may act on tissue leukocytes boosting
the inflammatory process while boosting immune status
as well. In this perspective, the attempt to treat peripheral
mononuclear cells of sepsis patients ex vivo with IL-2 be-
fore re-injecting them is an interesting approach that pre-
vents the delivery of this cytokine to the bloodstream,
allowing it to act strictly on the desired cells [86]. In this
study, the mortality was 8% in the extracorporeally treated
group of patients (n = 121) but was 21% in the patients re-
ceiving standard treatment (n = 52).
Approaches for innovative therapeutic
interventions
Rather than repeating the mistakes of past experimental
treatments for sepsis in which therapies were developed
after successful preclinical models that may be far from
mimicking human disease, it would be ideal to proceed
in the future with new treatments in which extensive hu-
man data are available prior to embarking on expensive
licensure studies. Furthermore, identifying currently li-
censed drugs with tolerable safety profiles as potential
sepsis agents leap-frogs costly drug development and
early-phase human studies.
In animal models, extant licensed drugs, such as chloro-
quine [87] and androstenenediol [51], have successfully re-
stored immune status. Most interestingly, in the latter
case, the treatment protected mice against polymicrobial
sepsis and boosted altered ex vivo cytokine production ob-
served with peripheral blood cells and spleen macro-
phages, dampening production observed with alveolar
macrophages and Kupffer cells. A similar compartmental-
ized adapted specificity was reported with estradiol [88].
Other approaches involve pro-resolving lipid mediators
[89], although it is uncertain whether they may also ad-
versely boost immune status. The recently recognized
aspirin-triggered lipoxins, anti-inflammatory mediators of
inflammation resolution, make aspirin a possible inexpen-
sive agent for both prevention and treatment of sepsis.
Considerable observational cohort data show improve-
ments in mortality in patients with sepsis pretreated with
aspirin [90]. This approach is being prospectively studied
as part of an aspirin primary prevention trial.
Could other immunomodulatory approaches be con-
sidered with less putative dangerous consequences on
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Indeed, a very promising study demonstrated its effi-
ciency to improve clinical outcome in patients with se-
vere sepsis [91], after a preliminary investigation had
demonstrated a better performance with respect to
organ failure scores in thymosin-α1-treated patients with
sepsis arising from intra-abdominal infection due to
carbapenem-resistant bacteria [92]. However, one must
call for caution since thymosin-α1 can also favor the
production of inflammatory cytokines and nitric oxide
and further increases the percentage of Treg cells [93,94].
Still, very little is known of its effect on leukocytes
present in different compartments.
The cell surface molecules containing in their intracy-
toplasmic domain an immunoreceptor tyrosine-based
inhibition motif - such as programmed death-1 (PD-1),
B and T lymphocyte attenuator (BTLA), and cytotoxic
T-lymphocyte antigen 4 (CTLA-4) - could also be inter-
esting targets for new therapeutic approaches. The ex-
pression of PD-1 on T cells and its ligand (PD-L1) on
monocytes is upregulated in critically ill [95] or septic
shock [96] patients. Increased expressions were associ-
ated with increased occurrence of secondary nosocomial
infections and mortality after septic shock [97]. Not only
are PD-1-deficient mice markedly protected from the le-
thality of sepsis, accompanied by a decreased bacterial
burden and suppressed inflammatory cytokine response
[98], but also blockade of PD-1 or PD-L1 improves sur-
vival in a murine model of sepsis, reverses immune dys-
function, inhibits lymphocyte apoptosis, and attenuates
organ dysfunction [99-101]. The relevance of these ob-
servations in human settings is still needed. CTLA-4 is aFigure 2 New therapeutic interventions should address both the even
immune status of leukocytes restricted to some specific compartmenhigh-avidity receptor for CD80 and CD86. Enhanced
CTLA-4 expression was demonstrated more frequently
in patients with sepsis than in non-infected critically ill
patients or control subjects [102], and blocking CTLA-4
improved survival in bacterial and fungal experimental
sepsis [103,104]. However, the use of such an approach
seems tricky since, in animal models at high dose, anti-
CTLA-4 could worsen survival [103], and the use of
Abatacept (a soluble CTLA-4 dimerized with an Fc frag-
ment of immunoglobulin) led to increased survival in in-
vasive pneumococcal infection [105]. Similarly, BTLA
expression is enhanced in patients with SIRS or sepsis
[106] and, in a murine model of sepsis, BTLA-deficient
mice displayed an enhanced resistance [107]. In contrast,
these mice displayed enhanced susceptibility to
endotoxin-induced shock [108]. Accordingly, the exact
role of BTLA needs to be further deciphered before
strategies targeting BTLA could be proposed to treat pa-
tients with sepsis.
Conclusions
New therapeutic approaches to treat sepsis should take
into consideration that the immune status of leukocytes in
the peripheral blood might be quite different from those
present in inflamed tissues. We believe that a systemic ap-
proach to immune stimulation is not appropriate if im-
mune cells are boosted generally, independent of their
location. An ideal drug would limit the overzealous in-
flammatory process that leads to organ failure and favor
homeostatic responsiveness of leukocytes (Figure 2). This
is the challenge we have to address if we wish to avoid
further decades of disillusionment.ts in the tissues that lead to organ failure and the altered
ts.
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PGE2: Prostaglandin E2; PM: Post-mortem; SIRS: Systemic inflammatory response
syndrome; SR-A: Scavenger receptor-A; TGFβ: Transforming growth factor-beta;
Th: T helper; TLR: Toll-like receptor; TNF: Tumor necrosis factor; Treg: Regulatory T
lymphocyte; VAP: Ventilator-associated pneumonia.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
J-MC and DE wrote the review. DA read and amended it. All authors read
and approved the final manuscript.
Author details
1Unit Cytokines & Inflammation, Institut Pasteur, 28 rue Dr. Roux, 75015 Paris,
France. 2Victorian Infectious Diseases Service, Royal Melbourne Hospital, 300
Grattan Street, Parkville 3050 Victoria, Australia. 3Department of Medicine,
Royal Melbourne Hospital, University of Melbourne, Victorian Infectious
Diseases Service, Royal Melbourne Hospital, 300 Grattan Street, Parkville 3050
Victoria, Australia. 4Intensive Care Unit, Hôpital Raymond Poincaré, 104,
boulevard Raymond-Poincaré, 92380 Garches, France.
Published:
References
1. Hotchkiss RS, Monneret G, Payen D: Immunosuppression in sepsis: a novel
understanding of the disorder and a new therapeutic approach. Lancet
Infect Dis 2013, 13:260–268.
2. Zakharova M, Ziegler HK: Paradoxical anti-inflammatory actions of
TNF-alpha: inhibition of IL-12 and IL-23 via TNF receptor 1 in
macrophages and dendritic cells. J Immunol 2005, 175:5024–5033.
3. Noti M, Corazza N, Mueller C, Berger B, Brunner T: TNF suppresses acute
intestinal inflammation by inducing local glucocorticoid synthesis.
J Exp Med 2010, 207:1057–1066.
4. González-Navajas JM, Law J, Nguyen KP, Bhargava M, Corr MP, Varki N,
Eckmann L, Hoffman HM, Lee J, Raz E: Interleukin 1 receptor signaling
regulates DUBA expression and facilitates toll-like receptor 9-driven
antiinflammatory cytokine production. J Exp Med 2010, 207:2799–2807.
5. Fukushima A, Ozaki A, Ishida W, Fukata K, Ueno H: Systemic
interferon-gamma suppresses the development of endotoxin-induced
uveitis in mice. Curr Eye Res 2005, 30:7–12.
6. Lauw FN, Pajkrt D, Hack CE, Kurimoto M, van Deventer SJH, van der Poll T:
Proinflammatory effects of IL-10 during human endotoxemia. J Immunol
2000, 165:2783–2789.
7. Petit-Bertron AF, Pedron T, Gross U, Coppée JY, Sansonetti PJ, Cavaillon JM,
Adib-Conquy M: Adherence modifies the regulation of gene expression
induced by interleukin-10. Cytokine 2005, 29:1–12.
8. Moore KW, De Waal Malefyt R, Coffman RL, O’Garra A: Interleukin-10 and
the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683–765.
9. Garcia-Lazaro JF, Thieringer F, Lüth S, Czochra P, Meyer E, Renteria IB, Galle
PR, Lohse AW, Herkel J, Kanzler S: Hepatic over-expression of TGF-beta1
promotes LPS-induced inflammatory cytokine secretion by liver cells and
endotoxemic shock. Immunol Lett 2005, 101:217–222.
10. Kalinski P: Regulation of immune responses by prostaglandin E2.
J Immunol 2012, 188:21–28.
11. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R,
Wenzel RP, Balk R, Allred R, Pennington JE, Wherry JC, Bellamy P, Cryer H,
Busuttil R, Winston D, Perry C, Leeper KV, Jones C, Martin M, Tuma P, Baird I,
Brooks J, Baird R, Rangel S, Wagner N, Costigan M, Gutierrez G, Johnson P,
et al: Efficacy and safety of monoclonal antibody to human tumor
necrosis factor alpha in patients with sepsis syndrome. A randomized,
24 Mar 2014controlled, double-blind, multicenter clinical trial. TNF-alpha MAb sepsis
study group. JAMA 1995, 273:934–941.
12. Reinhart K, Wiegand-Löhnert C, Grimminger F, Kaul M, Withington S,
Treacher D, Eckart J, Willatts S, Bouza C, Krausch D, Stockenhuber F,
Eiselstein J, Daum L, Kempeni J: Assessment of the safety and efficacy of
the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195 F,
in patients with sepsis and septic shock: a multicenter, randomized,
placebo-controlled, dose-ranging study. Crit Care Med 1996, 24:733–742.
13. Tetta C, Gianotti L, Cavaillon JM, Wratten ML, Fini M, Braga M, Bisagni P,
Giavaresi G, Bolzani R, Giardino R: Continuous plasmafiltration coupled
with sorbent adsorption in a rabbit model of endotoxic shock. Crit Care
Med 2000, 28:1526–1533.
14. Lorente JA, Marshall JC: Neutralization of tumor necrosis factor in
preclinical models of sepsis. Shock 2005, 24:107–119.
15. Miles RH, Paxton TP, Dries DJ, Gamelli RL: Interferon-gamma increases
mortality following cecal ligation and puncture. J Trauma 1994, 36:607–611.
16. Spight D, Trapnell B, Zhao B, Berclaz P, Shanley TP: Granulocyte-
macrophage-colony-stimulating factor-dependent peritoneal
macrophage responses determine survival in experimentally induced
peritonitis and sepsis in mice. Shock 2008, 30:434–442.
17. Reim D, Westenfelder K, Kaiser-Moore S, Schlautkotter S, Holzmann B,
Weighardt H: Role of T cells for cytokine production and outcome in a
model of acute septic peritonitis. Shock 2009, 31:245–250.
18. van Schaik SM, Abbas AK: Role of T cells in a murine model of Escherichia
coli sepsis. Eur J Immunol 2007, 37:3101–3110.
19. Heuer JG, Zhang T, Zhao J, Ding C, Cramer M, Justen KL, Vonderfecht SL,
Na S: Adoptive transfer of in vitro-stimulated CD4 + CD25+ regulatory T
cells increases bacterial clearance and improves survival in polymicrobial
sepsis. J Immunol 2005, 174:7141–7146.
20. Hiraki S, Ono S, Tsujimoto H, Kinoshita M, Takahata R, Miyazaki H, Saitoh D,
Hase K: Neutralization of interleukin-10 or transforming growth
factor-beta decreases the percentages of CD4+ CD25+ Foxp3+
regulatory T cells in septic mice, thereby leading to an improved
survival. Surgery 2012, 151:313–322.
21. Souza-Fonseca-Guimaraes F, Adib-Conquy M, Cavaillon JM: Natural killer
(NK) cells in antibacterial innate immunity: angels or devils? Mol Med
2012, 18:270–285.
22. Scumpia PO, McAuliffe PF, O’Malley KA, Ungaro R, Uchida T, Matsumoto T,
Remick DG, Clare-Salzler MJ, Moldawer LL, Efron PA: CD11c + dendritic cells
are required for survival in murine polymicrobial sepsis. J Immunol 2005,
175:3282–3286.
23. Maier M, Wutzler S, Bauer M, Trendafilov P, Henrich D, Marzi I: Altered gene
expression patterns in dendritic cells after severe trauma: implications
for systemic inflammation and organ injury. Shock 2008, 30:344–351.
24. Hotchkiss RS, Swanson PE, Knudson CM, Chang KC, Cobb JP, Osborne DF,
Zollner KM, Buchman TG, Korsmeyer SJ, Karl IE: Overexpression of Bcl-2 in
transgenic mice decreases apoptosis and improves survival in sepsis.
J Immunol 1999, 162:4148–4156.
25. Chen W, Frank M, Jin W, Wahl S: TGF-beta released by apoptotic T cells
contributes to an immunosuppressive milieu. Immunity 2001, 14:715–725.
26. Ren Y, Xie Y, Jiang G, Fan J, Yeung J, Li W, Tam PK, Savill J: Apoptotic cells
protect mice against lipopolysaccharide-induced shock. J Immunol 2008,
180:4978–4985.
27. Byrne A, Reen DJ: Lipopolysaccharide induces rapid production of IL-10
by monocytes in the presence of apoptotic neutrophils. J Immunol 2002,
168:1968–1977.
28. Perl M, Chung CS, Lomas-Neira J, Rachel TM, Biffl WL, Cioffi WG, Ayala A:
Silencing of Fas, but not caspase-8, in lung epithelial cells ameliorates
pulmonary apoptosis, inflammation, and neutrophil influx after
hemorrhagic shock and sepsis. Am J Pathol 2005, 167:1545–1559.
29. Glynne PA, Evans TJ: Inflammatory cytokines induce apoptotic and
necrotic cell shedding from human proximal tubular epithelial cell
monolayers. Kidney Int 1999, 55:2573–2597.
30. Husain KD, Stromberg PE, Woolsey CA, Turnbull IR, Dunne WM, Javadi P,
Buchman TG, Karl IE, Hotchkiss RS, Coopersmith CM: Mechanisms of
decreased intestinal epithelial proliferation and increased apoptosis in
murine acute lung injury. Crit Care Med 2005, 33:2350–2357.
31. Buerke U, Carter JM, Schlitt A, Russ M, Schmidt H, Sibelius U, Grandel U,
Grimminger F, Seeger W, Mueller-Werdan U, Werdan K, Buerke M: Apoptosis
contributes to septic cardiomyopathy and is improved by simvastatin
therapy. Shock 2008, 29:497–503.
Cavaillon et al. Critical Care Page 9 of 102014, 18:216
http://ccforum.com/content/18/2/21632. Zhou M, Simms HH, Wang P: Adrenomedullin and adrenomedullin
binding protein-1 attenuate vascular endothelial cell apoptosis in sepsis.
Ann Surg 2004, 240:321–330.
33. Sharshar T, Gray F, Lorin De La Grandmaison G, Hopkinson NS, Ross E,
Dorandeu A, Orlikowski D, Raphael JC, Gajdos P, Annane D: Apoptosis of
neurons in cardiovascular autonomic centres triggered by inducible
nitric oxide synthase after death from septic shock. Lancet 2003,
362:1799–1805.
34. Benjamim CF, Canetti C, Cunha FQ, Kunkel SL, Peters-Golden M: Opposing
and hierarchical roles of leukotrienes in local innate immune versus
vascular responses in a model of sepsis. J Immunol 2005, 174:1616–1620.
35. Park SW, Chen SW, Kim M, Brown KM, Kolls JK, D’Agati VD, Lee HT:
Cytokines induce small intestine and liver injury after renal ischemia or
nephrectomy. Lab Invest 2011, 91:63–84.
36. Lee HT, Kim M, Kim JY, Brown KM, Ham A, D’Agati VD, Mori-Akiyama Y:
Critical role of interleukin-17A in murine intestinal ischemia-reperfusion
injury. Am J Physiol Gastrointest Liver Physiol 2013, 304:G12–G25.
37. Bone RC, Grodzin CJ, Balk RA: Sepsis: a new hypothesis for pathogenesis
of the disease process. Chest 1997, 121:235–243.
38. Cavaillon J-M, Adib-Conquy M, Cloëz-Tayarani I, Fitting C: Immunodepression
in sepsis and SIRS assessed by ex vivo cytokine production is not a
generalized phenomenon: a review. J Endotoxin Res 2001, 7:85–93.
39. Tamayo E, Fernández A, Almansa R, Carrasco E, Heredia M, Lajo C,
Goncalves L, Gómez-Herreras JI, de Lejarazu RO, Bermejo-Martin JF:
Pro- and anti-inflammatory responses are regulated simultaneously from
the first moments of septic shock. Eur Cytokine Netw 2011, 22:82–87.
40. Tang BM, Huang SJ, McLean AS: Genome-wide transcription profiling of
human sepsis: a systematic review. Crit Care 2010, 14:R237.
41. Muñoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM: Dysregulation
of in vitro cytokine production by monocytes during sepsis. J Clin Invest
1991, 88:1747–1754.
42. Kim OY, Monsel A, Bertrand M, Coriat P, Cavaillon JM, Adib-Conquy M:
Differential down-regulation of HLA-DR on monocyte subpopulations
during systemic inflammation. Crit Care 2010, 14:R61.
43. Kox M, Timmermans K, Veaneker M, Scheffer G, Pickkers P: Immune
paralysis in trauma patients, implications for pre-hospital intervention.
Crit Care 2013, 17:9.
44. Adrie C, Adib-Conquy M, Laurent I, Monchi M, Vinsonneau C, Fitting C,
Fraisse F, Dinh-Xuan AT, Carli P, Spaulding C, Dhainaut JF, Cavaillon JM:
Successful cardiopulmonary resuscitation after cardiac arrest as a ‘sepsis
like’ syndrome. Circulation 2002, 106:562–568.
45. Gentile LF, Cuenca AG, Efron PA, Ang D, Bihorac A, McKinley BA, Moldawer
LL, Moore FA: Persistent inflammation and immunosuppression: a
common syndrome and new horizon for surgical intensive care.
J Trauma Acute Care Surg 2012, 72:1491–1501.
46. Danikas DD, Karakantza M, Theodorou GL, Sakellaropoulos GC, Gogos CA:
Prognostic value of phagocytic activity of neutrophils and monocytes in
sepsis. Correlation to CD64 and CD14 antigen expression. Clin Exp
Immunol 2008, 154:87–97.
47. Adib-Conquy M, Adrie C, Fitting C, Gattoliat O, Beyaert R, Cavaillon JM: Up-
regulation of MyD88s and SIGIRR, molecules inhibiting Toll-like receptor
signaling, in monocytes from septic patients. Crit Care Med 2006,
34:2377–2385.
48. Peck OM, Fan H, Tempel GE, Teti G, Halushka PV, Cook JA: Staphylococcus
aureus and lipopolysaccharide induce homologous tolerance but
heterologous priming: role of interferon-gamma. Shock 2004, 21:254–260.
49. Quintin J, Saeed S, Martens JH, Giamarellos-Bourboulis EJ, Ifrim DC, Logie C,
Jacobs L, Jansen T, Kullberg BJ, Wijmenga C, Joosten LA, Xavier RJ, van der
Meer JW, Stunnenberg HG, Netea MG: Candida albicans infection affords
protection against reinfection via functional reprogramming of
monocytes. Cell Host Microbe 2012, 12:223–232.
50. Cavaillon JM, Adrie C, Fitting C, Adib-Conquy M: Reprogramming of
circulatory cells in sepsis and SIRS. J Endotoxin Res 2005, 11:311–320.
51. Suzuki T, Shimizu T, Szalay L, Choudhry MA, Rue LW 3rd, Bland KI, Chaudry
IH: Androstenediol ameliorates alterations in immune cells cytokine
production capacity in a two-hit model of trauma-hemorrhage and
sepsis. Cytokine 2006, 34:76–84.
52. Neunaber C, Oestern S, Andruszkow H, Zeckey C, Mommsen P, Kutter D,
Stöfen M, Krettek C, Hildebrand F: Cytokine productive capacity of
alveolar macrophages and Kupffer cells after femoral fracture and blunt
chest trauma in a murine trauma model. Immunol Lett 2013, 152:159–166.53. Philippart F, Fitting C, Cavaillon JM: Lung microenvironment contributes
to the resistance of alveolar macrophages to develop tolerance to
endotoxin*. Crit Care Med 2012, 40:2987–2996.
54. Hoogerwerf JJ, de Vos AF, van’t Veer C, Bresser P, de Boer A, Tanck MW,
Draing C, van der Zee JS, van der Poll T: Priming of alveolar macrophages
upon instillation of lipopolysaccharide in the human lung. Am J Respir
Cell Mol Biol 2010, 42:349–356.
55. Zager RA, Johnson AC, Lund S: ‘Endotoxin tolerance’: TNF-alpha
hyper-reactivity and tubular cytoresistance in a renal cholesterol loading
state. Kidney Int 2007, 71:496–503.
56. Zurovsky Y, Eligal Z: Reduction of risk following endotoxin injection in
unilaterally nephrectomized rats. Exp Toxicol Pathol 1996, 48:41–46.
57. Zhang S, Kim CC, Batra S, McKerrow JH, Loke P: Delineation of diverse
macrophage activation programs in response to intracellular parasites
and cytokines. PLoS Negl Trop Dis 2010, 4:e648.
58. Hacham M, Cristal N, White RM, Segal S, Apte RN: Complementary organ
expression of IL-1 vs IL-6 and CSF-1 activities in normal and LPS injected
mice. Cytokine 1996, 8:21–31.
59. Raschke RA, Garcia-Orr R: Hemophagocytic lymphohistiocytosis: a potentially
underrecognized association with systemic inflammatory response syndrome,
severe sepsis, and septic shock in adults. Chest 2011, 140:933–938.
60. Ding Y, Chung CS, Newton S, Chen Y, Carlton S, Albina JE, Ayala A:
Polymicrobial sepsis induces divergent effects on splenic and peritoneal
dendritic cell function in mice. Shock 2004, 22:137–144.
61. Metzger DW, Salmon SL, Kirimanjeswara G: Differing effects of interleukin-10
on cutaneous and pulmonary Francisella tularensis live vaccine strain
infection. Infect Immun 2013, 81:2022–2027.
62. Blanchet C, Jouvion G, Fitting C, Cavaillon JM, Adib-Conquy M: Protective
or deleterious role of scavenger receptors SR-A and CD36 on host
resistance to Staphylococcus aureus depends on the site of infection.
PloS One 2014, 9:e87927.
63. Dorrington MG, Roche AM, Chauvin SE, Tu Z, Mossman KL, Weiser JN, Bowdish
DM: MARCO is required for TLR2- and Nod2-mediated responses to
Streptococcus pneumoniae and clearance of pneumococcal colonization in
the murine nasopharynx. J Immunol 2013, 190:250–258.
64. Pang G, Ortega M, Zighang R, Reeves G, Clancy R: Autocrine modulation of
IL-8 production by sputum neutrophils in chronic bronchial sepsis.
Am J Respir Crit Care Med 1997, 155:726–371.
65. Muenzer JT, Davis CG, Chang K, Schmidt RE, Dunne WM, Coopersmith CM,
Hotchkiss RS: Characterization and modulation of the
immunosuppressive phase of sepsis. Infect Immun 2010, 78:1582–15492.
66. Warren HS, Fitting C, Hoff E, Adib-Conquy M, Beasley-Topliffe L, Tesini B,
Liang X, Valentine C, Hellman J, Hayden D, Cavaillon JM: Resilience to
bacterial infection: difference between species could be due to proteins
in serum. J Infect Dis 2010, 201:223–232.
67. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR,
McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, López CM, Honari S,
Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB,
Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein
BH, Miller-Graziano C, Calvano SE, Mason PH, et al: Genomic responses in
mouse models poorly mimic human inflammatory diseases. Proc Natl
Acad Sci U S A 2013, 110:3507–3512.
68. Kapetanovic R, Fairbairn L, Beraldi D, Sester DP, Archibald AL, Tuggle CK,
Hume DA: Pig bone marrow-derived macrophages resemble human
macrophages in their response to bacterial lipopolysaccharide.
J Immunol 2012, 188:3382–3394.
69. Takahashi H, Tsuda Y, Takeuchi D, Kobayashi M, Herndon DN, Suzuki F:
Influence of systemic inflammatory response syndrome on host
resistance against bacterial infections. Crit Care Med 2004, 32:1879–1885.
70. Otto GP, Sossdorf M, Claus RA, Rödel J, Menge K, Reinhart K, Bauer M,
Riedemann NC: The late phase of sepsis is characterized by an increased
microbiological burden and death rate. Crit Care 2011, 15:R183.
71. Osawa R, Singh N: Cytomegalovirus infection in critically ill patients: a
systematic review. Crit Care 2009, 13:R68.
72. Luyt CE, Combes A, Deback C, Aubriot-Lorton MH, Nieszkowska A, Trouillet
JL, Capron F, Agut H, Gibert C, Chastre J: Herpes simplex virus lung
infection in patients undergoing prolonged mechanical ventilation.
Am J Respir Crit Care Med 2007, 175:935–942.
73. Torgersen C, Moser P, Luckner G, Mayr V, Jochberger S, Hasibeder WR,
Dünser MW: Macroscopic postmortem findings in 235 surgical intensive
care patients with sepsis. Anesth Analg 2009, 108:1841–1847.
Cavaillon et al. Critical Care Page 10 of 102014, 18:216
http://ccforum.com/content/18/2/21674. Döcke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD,
Kox W: Monocyte deactivation in septic patients: restoration by IFNg
treatment. Nature Med 1997, 3:678–681.
75. Wasserman D, Ioannovich JD, Hinzmann RD, Deichsel G, Steinmann GG:
Interferon-gamma in the prevention of severe burn-related infections: a
European phase III multicenter trial. The Severe Burns Study Group.
Crit Care Med 1998, 26:434–439.
76. Bo L, Wang F, Zhu J, Li J, Deng X: Granulocyte-colony stimulating factor
(G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF)
for sepsis: a meta-analysis. Crit Care 2011, 15:R58.
77. Verhoef G, Boogaerts M: Treatment with granulocyte-macrophage colony
stimulating factor and the adult respiratory distress syndrome.
Am J Hematol 1991, 36:285–287.
78. Bozinovski S, Jones J, Vlahos R, Hamilton J, Anderson G: Granulocyte/
macrophage-colony-stimulating factor (GM-CSF) regulates lung innate
immunity to lipopolysaccharide through Akt/Erk activation of NFkappa B
and AP-1 in vivo. J Biol Chem 2002, 277:42808–42814.
79. Khameneh HJ, Isa SA, Min L, Nih FW, Ruedl C: GM-CSF signalling boosts
dramatically IL-1 production. PLoS One 2011, 6:e23025.
80. Venet F, Foray AP, Villars-Méchin A, Malcus C, Poitevin-Later F, Lepape A,
Monneret G: IL-7 restores lymphocyte functions in septic patients.
J Immunol 2012, 189:5073–5081.
81. Sinha ML, Fry TJ, Fowler DH, Miller G, Mackall CL: Interleukin 7 worsens
graft-versus-host disease. Blood 2002, 100:2642–2649.
82. Willis CR, Seamons A, Maxwell J, Treuting PM, Nelson L, Chen G, Phelps S,
Smith CL, Brabb T, Iritani BM, Maggio-Price L: Interleukin-7 receptor
blockade suppresses adaptive and innate inflammatory responses in
experimental colitis. J Inflamm (Lond) 2012, 9:39.
83. Hartgring SA, Willis CR, Alcorn D, Nelson LJ, Bijlsma JW, Lafeber FP, van Roon
JA: Blockade of the interleukin-7 receptor inhibits collagen-induced arthritis
and is associated with reduction of T cell activity and proinflammatory
mediators. Arthritis Rheum 2010, 62:2716–2725.
84. Jin JO, Yu Q: Systemic administration of TLR3 agonist induces IL-7
expression and IL-7-dependent CXCR3 ligand production in the lung.
J Leukoc Biol 2013, 93:413–425.
85. Alderson MR, Tough TW, Ziegler SF, Grabstein KH: Interleukin 7 induces
cytokine secretion and tumoricidal activity by human peripheral blood
monocytes. J Exp Med 1991, 173:923–930.
86. Ostatin A, Paltsev A, Leplina O, Shevela Y, Chernykh H: The experience of
surgical infections treatment with extracorporal immunotherapy.
Medicinskaya Immunol 2000, 2:43–51.
87. Ertel W, Morrison MH, Ayala A, Chaudry IH: Chloroquine attenuates
hemorrhagic shock-induced immunosuppression and decreases
susceptibility to sepsis. Arch Surg 1992, 127:70–75.
88. Suzuki T, Shimizu T, Yu HP, Hsieh YC, Choudhry MA, Schwacha MG, Chaudry
IH: Tissue compartment-specific role of estrogen receptor subtypes in
immune cell cytokine production following trauma-hemorrhage.
J Appl Physiol 2007, 102:163–168.
89. Chiang N, Fredman G, Bäckhed F, Oh SF, Vickery T, Schmidt BA, Serhan CN:
Infection regulates pro-resolving mediators that lower antibiotic
requirements. Nature 2012, 484:524–528.
90. Eisen DP, Reid D, McBryde ES: Acetyl salicylic acid usage and mortality in
critically ill patients with the systemic inflammatory response syndrome
and sepsis. Crit Care Med 2012, 40:1761–1767.
91. Wu J, Zhou L, Liu J, Ma G, Kou Q, He Z, Chen J, Ou-Yang B, Chen M, Li Y,
Wu X, Gu B, Chen L, Zou Z, Qiang X, Chen Y, Lin A, Zhang G, Guan X: The
efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter,
single-blind, randomized and controlled trial. Crit Care 2013, 17:R8.
92. Zhang Y, Chen H, Li YM, Zheng SS, Chen YG, Li LJ, Zhou L, Xie HY, Praseedom
RK: Thymosin alpha1- and ulinastatin-based immunomodulatory strategy
for sepsis arising from intra-abdominal infection due to carbapenem-
resistant bacteria. J Infect Dis 2008, 198:723–730.
93. Sodhi A, Paul S: Involvement of mitogen-activated protein kinases in the
signal transduction pathway of bone marrow-derived macrophage
activation in response to in vitro treatment with thymosin alpha 1.
Int Immunopharmacol 2002, 2:47–58.
94. Yang X, Qian F, He HY, Liu KJ, Lan YZ, Ni B, Tian Y, Fu XL, Zhang J, Shen ZG,
Li J, Yin Y, Li JT, Wu YZ: Effect of thymosin alpha-1 on subpopulations of
Th1, Th2, Th17, and regulatory T cells (Tregs) in vitro. Braz J Med Biol Res
2012, 45:25–32.95. Monaghan SF, Thakkar RK, Tran ML, Huang X, Cioffi WG, Ayala A, Heffernan
DS: Programmed death 1 expression as a marker for immune and
physiological dysfunction in the critically ill surgical patient. Shock 2012,
38:117–122.
96. Zhang Y, Li J, Lou J, Zhou Y, Bo L, Zhu J, Zhu K, Wan X, Cai Z, Deng X:
Upregulation of programmed death-1 on T cells and programmed death
ligand-1 on monocytes in septic shock patients. Crit Care 2011, 15:R70.
97. Guignant C, Lepape A, Huang X, Kherouf H, Denis L, Poitevin F, Malcus C,
Chéron A, Allaouchiche B, Gueyffier F, Ayala A, Monneret G, Venet F:
Programmed death-1 levels correlate with increased mortality,
nosocomial infection and immune dysfunctions in septic shock patients.
Crit Care 2011, 15:R99.
98. Huang X, Venet F, Wang YL, Lepape A, Yuan Z, Chen Y, Swan R, Kherouf H,
Monneret G, Chung CS, Ayala A: PD-1 expression by macrophages plays a
pathologic role in altering microbial clearance and the innate inflammatory
response to sepsis. Proc Natl Acad Sci U S A 2009, 106:6303–6308.
99. Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS:
Delayed administration of anti-PD-1 antibody reverses immune dysfunction
and improves survival during sepsis. J Leukoc Biol 2010, 88:233–240.
100. Zhang Y, Zhou Y, Lou J, Li J, Bo L, Zhu K, Wan X, Deng X, Cai Z: PD-L1
blockade improves survival in experimental sepsis by inhibiting
lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care
2010, 14:R220.
101. Zhu W, Bao R, Fan X, Tao T, Zhu J, Wang J, Li J, Bo L, Deng X: PD-L1
blockade attenuated sepsis-induced liver injury in a mouse cecal ligation
and puncture model. Mediators Inflamm 2013, 2013:361501.
102. Manjuck J, Saha DC, Astiz M, Eales LJ, Rackow EC: Decreased response to
recall antigens is associated with depressed costimulatory receptor
expression in septic critically ill patients. J Lab Clin Med 2000, 135:153–160.
103. Inoue S, Bo L, Bian J, Unsinger J, Chang K, Hotchkiss RS: Dose-dependent
effect of anti-CTLA-4 on survival in sepsis. Shock 2011, 36:38–44.
104. Chang KC, Burnham CA, Compton SM, Rasche DP, Mazuski R, Smcdonough
J, Unsinger J, Korman AJ, Green JM, Hotchkiss RS: Blockade of the negative
co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary
and secondary fungal sepsis. Crit Care 2013, 17:R85.
105. LeMessurier K, Häcker H, Tuomanen E, Redecke V: Inhibition of T cells
provides protection against early invasive pneumococcal disease.
Infect Immun 2010, 78:5287–5294.
106. Shubin NJ, Monaghan SF, Heffernan DS, Chung CS, Ayala A: B and T
lymphocyte attenuator expression on CD4+ T-cells associates with sepsis
and subsequent infections in ICU patients. Crit Care 2013, 17:R276.
107. Shubin NJ, Chung CS, Heffernan DS, Irwin LR, Monaghan SF, Ayala A: BTLA
expression contributes to septic morbidity and mortality by inducing
innate inflammatory cell dysfunction. J Leukoc Biol 2012, 92:593–603.
108. Kobayashi Y, Iwata A, Suzuki K, Suto A, Kawashima S, Saito Y, Owada T, Kobayashi
M, Watanabe N, Nakajima H: B and T lymphocyte attenuator inhibits
LPS-induced endotoxic shock by suppressing Toll-like receptor 4 signaling in
innate immune cells. Proc Natl Acad Sci U S A 2013, 110:5121–5126.
Cite this article as: Cavaillon et al.: Is boosting the immune system in
sepsis appropriate? Critical Care
10.1186/cc13787
2014, 18:216
